Abstral to be released in France for cancer pain management
Reported July 11, 200
9
A new cancer pain treatment drug, Abstral, will be released in France this month by the pharmaceutical company ProStrakan Group. ProStrakan Group has completed the reimbursement pricing process with French authorities for the product launch.
The cancer drug Abstral is a new formulation of fentanyl. It can be used by cancer patients who are already using opioid analgesics for their pain management. The drug will help manage breakthrough pain episodes.
Abstral was recommended and approved in the European Union by the Committee for Medicinal Products for Human Use of the European Medicines Agency in June 2008. Regulators in France authorized the marketing for Abstral on February 23, 2009. Abstral has been available in Germany and the UK since January 2009.
Source : Mesothelioma News